CA2406403A1 - Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof - Google Patents
Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof Download PDFInfo
- Publication number
- CA2406403A1 CA2406403A1 CA002406403A CA2406403A CA2406403A1 CA 2406403 A1 CA2406403 A1 CA 2406403A1 CA 002406403 A CA002406403 A CA 002406403A CA 2406403 A CA2406403 A CA 2406403A CA 2406403 A1 CA2406403 A1 CA 2406403A1
- Authority
- CA
- Canada
- Prior art keywords
- toxic
- ribozyme
- pathogen
- nucleic acid
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54844900A | 2000-04-13 | 2000-04-13 | |
US09/548,449 | 2000-04-13 | ||
US25181000P | 2000-12-07 | 2000-12-07 | |
US60/251,810 | 2000-12-07 | ||
PCT/US2001/012130 WO2001079524A2 (en) | 2000-04-13 | 2001-04-13 | Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2406403A1 true CA2406403A1 (en) | 2001-10-25 |
Family
ID=26941841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002406403A Abandoned CA2406403A1 (en) | 2000-04-13 | 2001-04-13 | Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1397489A4 (xx) |
JP (1) | JP2004525602A (xx) |
AU (2) | AU5347101A (xx) |
CA (1) | CA2406403A1 (xx) |
WO (1) | WO2001079524A2 (xx) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101202974B1 (ko) * | 2003-06-13 | 2012-11-21 | 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 | Rna 인터페라제 및 이의 사용 방법 |
WO2005046579A2 (en) * | 2003-10-06 | 2005-05-26 | Gangagen, Inc. | Defined dose therapeutic phage |
SG10201805660WA (en) | 2013-12-30 | 2018-08-30 | Curevac Ag | Methods for rna analysis |
US20210022324A1 (en) * | 2018-03-05 | 2021-01-28 | Dr. Reddy's Institute Of Life Sciences | Embryonic zebrafish models using dnazyme mediated knockdown |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991008312A1 (en) * | 1989-12-01 | 1991-06-13 | Gene-Trak Systems | Detection of hpv transcripts |
GB9015845D0 (en) * | 1990-07-19 | 1990-09-05 | Emery Vincent C | Diagnostic method |
FR2679254B1 (fr) * | 1991-07-17 | 1993-11-19 | Clonatec | Sondes oligonucleotidiques pour le typage et la detection des papillomavirus humains. |
WO1993023569A1 (en) * | 1992-05-11 | 1993-11-25 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting viral replication |
US5767259A (en) * | 1994-12-27 | 1998-06-16 | Naxcor | Oligonucleotides containing base-free linking groups with photoactivatable side chains |
CA2139623A1 (en) * | 1993-05-06 | 1994-11-24 | Baxter Diagnostics Inc. | Human papillomavirus detection assay |
US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
US5989804A (en) * | 1994-07-08 | 1999-11-23 | New England Medical Center Hospitals, Inc. | E6 binding proteins |
US5985662A (en) * | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
AU5298699A (en) * | 1998-08-13 | 2000-03-06 | Johnson & Johnson Research Pty. Limited | Dnazymes and methods for treating hpv-related disorders |
EP1353935A4 (en) * | 2000-12-07 | 2005-02-23 | Penn State Res Found | SELECTION OF TARGET CATALYTIC NUCLEIC ACIDS ON INFECTIOUS AGENTS |
-
2001
- 2001-04-13 AU AU5347101A patent/AU5347101A/xx active Pending
- 2001-04-13 JP JP2001577507A patent/JP2004525602A/ja active Pending
- 2001-04-13 CA CA002406403A patent/CA2406403A1/en not_active Abandoned
- 2001-04-13 AU AU2001253471A patent/AU2001253471B2/en not_active Ceased
- 2001-04-13 EP EP01926973A patent/EP1397489A4/en not_active Withdrawn
- 2001-04-13 WO PCT/US2001/012130 patent/WO2001079524A2/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
WO2001079524A2 (en) | 2001-10-25 |
WO2001079524A3 (en) | 2004-01-08 |
JP2004525602A (ja) | 2004-08-26 |
EP1397489A4 (en) | 2005-05-11 |
EP1397489A2 (en) | 2004-03-17 |
AU5347101A (en) | 2001-10-30 |
AU2001253471B2 (en) | 2007-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060223774A1 (en) | Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof | |
US6271359B1 (en) | Tissue-specific and pathogen-specific toxic agents and ribozymes | |
US20040220123A1 (en) | Tissue-specific and pathogens-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof | |
DE69734589T2 (de) | Antitumor antisense sequenzen gegen h1 und r2 verbindungen von ribonukleotide reductase | |
CN111133107A (zh) | 用于治疗性核酸递送的跨界平台 | |
US8921335B2 (en) | Oral delivery of nucleic acid-based gene interfering agents by Salmonella | |
US7732197B2 (en) | Tissue-specific and target RNA-specific ribozymes | |
AU2001253471B2 (en) | Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof | |
AU2001253471A1 (en) | Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof | |
WO2021021636A1 (en) | Oligonucleotide antagonists for rna guided genome editing | |
AU2004265550A1 (en) | RNA interference compositions and methods | |
WO1998024925A1 (en) | Tissue specific and target rna-specific ribozymes as antimicrobial therapeutics against microbial pathogens | |
EP1702983A2 (en) | Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of use thereof | |
US20090156794A1 (en) | Compositions and methods for activating genes of interest | |
US20030032612A1 (en) | Oligonucleotides specific for the marORAB operon | |
US20170233760A1 (en) | Biologically active nucleotide molecules for selectively killing off cells, use thereof, and application kit | |
AU743119B2 (en) | Tissue specific and target RNA-specific ribozymes as antimicrobial therapeutics against microbial pathogens | |
US20030125280A1 (en) | Tissue specific and target RNA-specific ribozymes as antimicrobial therapeutics against microbial pathogens | |
AU2004201285B2 (en) | Tissue-specific and target RNA-specific ribozymes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |